The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
A Prospective Trial of Modafinil as an Adjunctive Treatment of Major Depression
Abstract
Modafinil is a wake-promoting agent approved by the Federal Drug Administration for the treatment of narcolepsy. Preliminary evidence indicates that modafinil may improve fatigue and excessive sleepiness associated with a variety of conditions. The purpose of this study was to investigate the utility of modafinil as an adjunctive treatment of depressed patients. Subjects with a history of major depression with partial response on a stable therapeutic dose of an antidepressant were eligible to participate. All subjects endorsed complaints of significant fatigue and/or excessive sleepiness on clinical assessment. Modafinil was added to their existing regimen at a dose of 100 to 400 mg/d for 4 weeks. Subjects were assessed at 2-week intervals for improvement using the standard depression scales (HDRS, BDI, CGI), fatigue scales (VASF, FSI), and a neuropsychologic battery. Thirty-five subjects were entered and 31 subjects completed the 4-week trial. Significant improvements were seen across all 3 measures of depression (HDRS, BDI, CGIS) and both measures of fatigue (VASF, FSI). On the neurocognitive battery, significant gains in the Stroop Interference Test were seen at 4 weeks, whereas the other cognitive tests showed no change. Modafinil may be a useful and a well-tolerated adjunctive agent to standard antidepressants in the treatment of major depression.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and increase feature-based selective attention and clinical symptoms in depressed patients119.”
From Paying attention to attention in depression (2019) · cites this paper as [119]
In the citing paper
“Modafinil has only been tested as a procognitive agent for MDD in a 4-week open-label trial, enrolling 35 patients with MDD with a partial response to an antidepressant at a stable dose [147].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [147]
In the citing paper
“However, neurocognitive function was not a primary outcome of this small, uncontrolled trial.”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [147]
Citations
Cites
Rammohan, K. W. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.2.179 · Cited by 441
Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy
Fry (1998) · Annals of Neurology · doi:10.1002/ana.410430115 · Cited by 398
Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy
US Modafinil in Narcolepsy Multicenter Study Group (2000) · Neurology · doi:10.1212/wnl.54.5.1166 · Cited by 363
Modafinil as Adjunct Therapy for Daytime Sleepiness in Obstructive Sleep Apnea
PACK, A. I., BLACK, J. E., SCHWARTZ, J. R. L., & MATHESON, J. K. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.9.2103032 · Cited by 324
Broughton, R., Fleming, J. A. E., George, C. F., Hill, J. D., Kryger, M. H., Moldofsky, H., Montplaisir, J. Y., Morehouse, R. L., Moscovitch, A., & Murphy, W. F. (1997) · Neurology · doi:10.1212/wnl.49.2.444 · Cited by 285
Naps and modafinil as countermeasures for the effects of sleep deprivation on cognitive performance.
Batéjat, D., & Lagarde, D. (1999) · PubMed · Cited by 234
Tylee, A. T., Gastpar, M., Lépine, J., & MENDLEWICZ, J. (1999) · International Clinical Psychopharmacology · doi:10.1097/00004850-199905002-00001 · Cited by 221
Modafinil Augmentation of Antidepressant Treatment in Depression
Menza, M. A., Kaufman, K. R., & Castellanos, A. M. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0510 · Cited by 200
TAYLOR, F. B., & Russo, J. E. (2000) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2000.10.311 · Cited by 182
A Potential Clinical Use for Methylphenidate with Tricyclic Antidepressants
Wharton, R. N., Perel, J. M., Dayton, P. G., & Malitz, S. (1971) · American Journal of Psychiatry · doi:10.1176/ajp.127.12.1619 · Cited by 134
Research works printed but not linked: 1
- 1998, US Modafinil in Narcolepsy Multicenter Study Group., Ann Neurol, 43, 88
Cited by
Sorted by citations
Cognitive impairment in depression: a systematic review and meta-analysis
Rock, P. L., Roiser, J. P., Riedel, W. J., & Blackwell, A. D. (2014) · Psychological Medicine · doi:10.1017/s0033291713002535 · Cited by 2,161
“Indeed, 4-week adjunctive treatment with modafinil was shown to improve performance on a task of executive function in currently depressed patients with only partial response to antidepressant therapy (DeBattista et al. 2004).”
BackgroundPRACTICE GUIDELINE FOR THE Treatment of Patients With Major Depressive Disorder
Gelenberg, A. J., Freeman, P. B., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., & Rhoads, R. S. (2010) · Cited by 1,372
Modafinil: a review of neurochemical actions and effects on cognition
Minzenberg, M. J., & Carter, C. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301534 · Cited by 713
“%) qd Performance at 30 mg/kg Ward et al, 2004 Cognitive battery Rat 0, 8, 32, 64 mg/kg i.p. m Accuracy, kRT and k premature responses on 3-choice visual attention task with long delay at 64 mg/kg only Visual discrimination performance; omission errors or measures of motivation or motor activity Morgan et al, 2007 5-C…”
BackgroundInfluentialCognitive Mechanisms of Treatment in Depression
Roiser, J. P., Elliott, R., & Sahakian, B. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.183 · Cited by 535
Millan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 569
Metadata
- Authors
- DeBattista, C., Lembke, A., Solvason, H. B., Ghebremichael, R., & Poirier, J.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- DeBattista, Charles
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2004-02
- Volume
- 24
- Issue
- 1
- Pages
- 87-90
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1986635669
- Cited by
- 144
- References
- 24
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2023: 2 · 2022: 1 · 2021: 4 · 2020: 5 · 2019: 8 · 2018: 2 · 2017: 2 · 2016: 5 · 2015: 6 · 2014: 4 · 2013: 7 · 2012: 3
- FWCI
- 12.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- modafinil, major depressive disorder, adjunctive therapy, fatigue, excessive sleepiness, wakefulness-promoting agents, antidepressant response, cognitive function, Stroop interference, neuropsychological assessment
- MeSH terms
- Modafinil, Adult, Aged, Antidepressive Agents, Benzhydryl Compounds, Major Depressive Disorder, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Drug Tolerance, Fatigue, Female, Humans, Disorders of Excessive Somnolence, Male, Middle Aged, Prospective Studies, Psychiatric Status Rating Scales, Time Factors, Treatment Outcome, Diagnostic and Statistical Manual of Mental Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
